UPM Biomedicals is the forerunner in producing high quality nanofibrillar cellulose for medical and life science applications. More than 300 patents protect the existing and future products that rely on the Finnish birch pulp. We actively collaborate with universities, research centers and key industrial partners on future innovations and products in the field of high throughput drug screening, personalized medicine, advanced cell therapies, 3D bioprinting, tissue engineering and advanced wound care.
We are part of UPM, the Biofore Company that creates value from renewable and recyclable materials. In 2022, UPM’s sales were approximately EUR 11.7 billion. UPM has production plants in 12 countries and a global sales network. UPM employs approximately 17,200 employees worldwide. UPM shares are listed on the NASDAQ OMX Helsinki stock exchange. At the end of 2022, UPM had approximately 132,100 shareholders.
